KR102497242B1 - 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법 - Google Patents

당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR102497242B1
KR102497242B1 KR1020197015784A KR20197015784A KR102497242B1 KR 102497242 B1 KR102497242 B1 KR 102497242B1 KR 1020197015784 A KR1020197015784 A KR 1020197015784A KR 20197015784 A KR20197015784 A KR 20197015784A KR 102497242 B1 KR102497242 B1 KR 102497242B1
Authority
KR
South Korea
Prior art keywords
formulation
img
seq
gly
rps2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197015784A
Other languages
English (en)
Korean (ko)
Other versions
KR20190084070A (ko
Inventor
응옥 타이
조나단 폴레트
Original Assignee
이매진 파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이매진 파마 filed Critical 이매진 파마
Publication of KR20190084070A publication Critical patent/KR20190084070A/ko
Application granted granted Critical
Publication of KR102497242B1 publication Critical patent/KR102497242B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020197015784A 2016-11-13 2017-11-13 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법 Active KR102497242B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
US62/421,332 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (2)

Publication Number Publication Date
KR20190084070A KR20190084070A (ko) 2019-07-15
KR102497242B1 true KR102497242B1 (ko) 2023-02-09

Family

ID=62107069

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197015784A Active KR102497242B1 (ko) 2016-11-13 2017-11-13 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (2) US10548941B2 (enExample)
EP (1) EP3538124A4 (enExample)
JP (3) JP2020502056A (enExample)
KR (1) KR102497242B1 (enExample)
CN (1) CN110087666B (enExample)
AU (2) AU2017357052B2 (enExample)
BR (1) BR112019009511A2 (enExample)
MX (1) MX2019005466A (enExample)
WO (1) WO2018089909A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
KR20210013543A (ko) * 2018-01-09 2021-02-04 이매진 파마 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
CA3104901A1 (en) * 2018-06-25 2020-01-02 Imagine Pharma, Llc Compositions and methods for propagating insulin-producing islet cells and therapeutic uses thereof
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
PE20240888A1 (es) * 2020-12-08 2024-04-24 Imagine Pharma Llc Composiciones y metodos para tratar heridas
IL311468A (en) * 2021-09-22 2024-05-01 Imagine Pharma Llc Compositions and methods for the proliferation of insulin- and glucagon-secreting cells from type 1 diabetic pancreatic tissue and their therapeutic uses
IL312382A (en) * 2021-12-11 2024-06-01 Imagine Pharma Llc COMPOUNDS AND METHODS OF ORAL ADMINISTRATION
WO2025207834A1 (en) * 2024-03-28 2025-10-02 Imagine Pharma Llc Dietary supplements, compositions, and uses thereof for increasing telomerase activity and extending telomere length

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537274A (ja) 2001-02-15 2004-12-16 コンドロジェネシス ピーティーワイ リミテッド 軟骨形成におけるマトリックス遺伝子発現
US20160120999A1 (en) 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3917258B2 (ja) * 1997-04-09 2007-05-23 花王株式会社 新規アルカリペクチン酸リアーゼ及びその製造法
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2275120A3 (en) * 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
CA2527957A1 (en) * 2003-06-02 2005-01-06 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
US20090048199A1 (en) * 2007-03-09 2009-02-19 Hiberna Corporation Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use
US9221886B2 (en) * 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2012054739A2 (en) * 2010-10-21 2012-04-26 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
CA2817851A1 (en) * 2010-11-12 2012-05-18 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
DK3447061T3 (da) 2011-03-01 2022-01-03 NuCana plc Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling
EP3048904A2 (en) * 2013-09-25 2016-08-03 Pronutria Biosciences, Inc. Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
EP3538124A4 (en) 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
KR20210013543A (ko) * 2018-01-09 2021-02-04 이매진 파마 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537274A (ja) 2001-02-15 2004-12-16 コンドロジェネシス ピーティーワイ リミテッド 軟骨形成におけるマトリックス遺伝子発現
US20160120999A1 (en) 2014-10-31 2016-05-05 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank: BAC16801.1, ribosomal protein S2 [Homo sapiens] (2002. 9.28.)*

Also Published As

Publication number Publication date
US20200222499A1 (en) 2020-07-16
AU2017357052A1 (en) 2019-05-02
JP2020502056A (ja) 2020-01-23
CA3041362A1 (en) 2018-05-17
EP3538124A1 (en) 2019-09-18
US20180133280A1 (en) 2018-05-17
JP2023071670A (ja) 2023-05-23
US10548941B2 (en) 2020-02-04
JP2025163025A (ja) 2025-10-28
AU2022203741B2 (en) 2024-02-15
CN110087666B (zh) 2024-04-30
AU2022203741A1 (en) 2022-06-23
US10751384B2 (en) 2020-08-25
AU2017357052B2 (en) 2022-03-24
CN110087666A (zh) 2019-08-02
JP7711967B2 (ja) 2025-07-23
KR20190084070A (ko) 2019-07-15
WO2018089909A1 (en) 2018-05-17
BR112019009511A2 (pt) 2019-07-30
EP3538124A4 (en) 2020-07-22
MX2019005466A (es) 2019-10-02

Similar Documents

Publication Publication Date Title
AU2022203741B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20200353054A1 (en) Use of ave0010 for the treatment of diabetes mellitus type 2
EP3268029B1 (en) Treatment of type 2 diabetes mellitus patients
EP3670529B1 (en) Acylated oxyntomodulin peptide analog
CN112279920A (zh) FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
US20080194483A1 (en) GLP-1 (9-36) methods and compositions
US11612637B2 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
US20230263856A1 (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
CA3041362C (en) Compositions and methods for treating diabetes, hypertension and hypercholesterolemia
TWI848060B (zh) 重組蛋白用於治療代謝疾病
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
WO2019037393A1 (zh) 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用
TW202506170A (zh) 糖尿病之治療
US20210213104A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
CN113476591A (zh) 一种乳源多肽衍生物在制备糖尿病防治药物、保健品以及食品添加物中的应用
CN111744006A (zh) 一种用于防治糖尿病视网膜病变的药物组合物
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
WO2010121351A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4